Jacob Plieth

@JacobPlieth · London, UK · joined 11 Oct 2012

Journalist @ApexOnco. The Wolverine Of Biotech / Mr ASH. Interested in: oncology. Not interested in: what stock you bought today. My internal plan is as follows

33 172Followers

284Following

29 127Posts total

37.1KViews on collected posts

Postingan terbaru

Jacob Plieth@JacobPlieth14 Sep

Nice Arros-1 vs Trust I/II vs Trident-1 cross-trial comparisons by #WCLC26 discussant Malinda Itchins. Pretty clear $GSK got the better drug (at a price). $NUVB https://t.co/VsJJ5w2MNE

2.8K views · 25 likes · 7 reposts · 2 replies Open on X →

Jacob Plieth@JacobPlieth14 Sep

Meanwhile, $AZN $DSNKY are filing on these data. Sure, why not? #WCLC26 https://t.co/0Xg2UjpZGD

2.8K views · 17 likes · 0 reposts · 1 replies Open on X →

Jacob Plieth@JacobPlieth14 Sep

Here's an important detail from #WCLC26 about Harmoni-2: the positive OS data are from a 2nd interim analysis, conducted at 234 events. Sig threshold was 1-sided alpha of 0.0141 $SMMT https://t.co/eUIxR5VJp1

1.4K views · 2 likes · 0 reposts · 1 replies Open on X →

Jacob Plieth@JacobPlieth13 Sep

@JacobPlieth Still inferior to sac-TMT, correct? 3.7K views · 6 likes · 0 reposts · 6 replies Open on X →

Jacob Plieth@JacobPlieth13 Sep

In Harmoni-2 Keytruda outperformed KN-042, and still $SMMT ivonescimab beat it on OS. Yes, I know KN-042 is 10 years old, and I know these are China data, but still this is good. HR=0.73 beats analyst expectations (~0.77) #WCLC26 https://t.co/Dfiw9kCUDc

12.7K views · 62 likes · 13 reposts · 7 replies Open on X →

Jacob Plieth@JacobPlieth12 Sep

$BNTX $BMY pumitamig + B7-H3 might be better than either agent alone. Via @ByMadeleineA @ApexOnco from #WCLC26 -> https://t.co/SlJ8R1OrBH $SMMT 6.8K views · 30 likes · 7 reposts · 2 replies Open on X →

Jacob Plieth@JacobPlieth9 Sep

First-line accelerated approval for Bayer's Hyrnuo https://t.co/RR7D2rIuuh 6.8K views · 13 likes · 2 reposts · 0 replies Open on X →

Dibandingkan akun berukuran sama

7 postingan dari 90 hari terakhir, dibandingkan dengan rentang 10K–100K pengikut. tampil luas, tetapi sedikit penonton yang merespons.

Median tayangan3 708akun ini955median untuk 10K–100K

Jangkauan, %11.18%akun ini3.52%median untuk 10K–100K

Interaksi, %0.57%akun ini1.56%median untuk 10K–100K

Metrik	Akun ini	Median untuk 10K–100K	Rasio
Median tayangan per postingan	3 708	955	3.88×
Jangkauan (tayangan ÷ pengikut)	11.18%	3.52%	3.18×
Tingkat interaksi	0.57%	1.56%	0.37×

Akun lain pada rentang ini → Bandingkan dengan akun lain → Bagaimana tolok ukur ini disusun →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

6.8K9 Sep

6.8K12 Sep

12.7K13 Sep

3.7K

1.4K14 Sep

2.8K

Last 7 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.22%9 Sep

0.58%12 Sep

0.64%13 Sep

0.32%

0.22%14 Sep

0.64%

1.20%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.56%.

What the audience does

Likes59.8%155 in total

Reposts11.2%29 in total

Replies7.3%19 in total

Bookmarks21.6%56 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Postingan terbaru

Dibandingkan akun berukuran sama

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Akun serupa